These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 27438818)

  • 1. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
    Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
    J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
    Li Q; Kang C
    Molecules; 2020 Jun; 25(13):. PubMed ID: 32605297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor.
    Khattri RB; Morris DL; Davis CM; Bilinovich SM; Caras AJ; Panzner MJ; Debord MA; Leeper TC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR in structure-based drug design.
    Carneiro MG; Ab E; Theisgen S; Siegal G
    Essays Biochem; 2017 Nov; 61(5):485-493. PubMed ID: 29118095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Virtual Screening.
    Li Q; Shah S
    Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors.
    Martinez-Rosell G; Harvey MJ; De Fabritiis G
    J Chem Inf Model; 2018 Mar; 58(3):683-691. PubMed ID: 29481075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Protein- and Ligand-Observed NMR Workflow to Screen Fragment Cocktails against Multiple Proteins: A Case Study Using Bromodomains.
    Johnson JA; Olson NM; Tooker MJ; Bur SK; Pomerantz WCK
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of inhibitors targeting N-Terminal domain of human Replication Protein A.
    Çınaroğlu SS; Timuçin E
    J Mol Graph Model; 2019 Jan; 86():149-159. PubMed ID: 30366191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine.
    Vulpetti A; Hommel U; Landrum G; Lewis R; Dalvit C
    J Am Chem Soc; 2009 Sep; 131(36):12949-59. PubMed ID: 19702332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
    Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
    J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in Docking and Molecular Dynamics Simulations Towards Ligand-receptor Interactions and Structure-function Relationships.
    Naqvi AAT; Mohammad T; Hasan GM; Hassan MI
    Curr Top Med Chem; 2018; 18(20):1755-1768. PubMed ID: 30360721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein structure-based drug design: from docking to molecular dynamics.
    Śledź P; Caflisch A
    Curr Opin Struct Biol; 2018 Feb; 48():93-102. PubMed ID: 29149726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.